Integrated Wealth Concepts LLC Takes $244,000 Position in DexCom, Inc. (NASDAQ:DXCM)

Integrated Wealth Concepts LLC bought a new position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 3,133 shares of the medical device company's stock, valued at approximately $244,000.

Other large investors have also recently bought and sold shares of the company. Wilmington Savings Fund Society FSB acquired a new stake in shares of DexCom in the third quarter worth $381,000. Tidal Investments LLC grew its position in DexCom by 68.0% during the 3rd quarter. Tidal Investments LLC now owns 36,742 shares of the medical device company's stock worth $2,463,000 after purchasing an additional 14,872 shares during the period. B. Riley Wealth Advisors Inc. raised its stake in shares of DexCom by 42.3% during the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 5,590 shares of the medical device company's stock valued at $370,000 after buying an additional 1,662 shares during the last quarter. Versant Capital Management Inc acquired a new position in shares of DexCom in the 4th quarter valued at about $25,000. Finally, GAMMA Investing LLC boosted its stake in shares of DexCom by 47.6% in the fourth quarter. GAMMA Investing LLC now owns 8,258 shares of the medical device company's stock worth $642,000 after buying an additional 2,665 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company's stock.

Insider Buying and Selling

In related news, CEO Kevin R. Sayer sold 32,498 shares of the business's stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $2,287,209.24. Following the sale, the chief executive officer now directly owns 372,029 shares in the company, valued at approximately $26,183,401.02. The trade was a 8.03 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Jacob Steven Leach sold 14,076 shares of the stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total transaction of $990,668.88. Following the transaction, the chief operating officer now directly owns 313,497 shares of the company's stock, valued at approximately $22,063,918.86. This trade represents a 4.30 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 66,926 shares of company stock worth $4,734,384. Company insiders own 0.32% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on DXCM. Baird R W raised DexCom from a "hold" rating to a "strong-buy" rating in a report on Thursday, January 16th. Canaccord Genuity Group raised their price target on shares of DexCom from $103.00 to $106.00 and gave the company a "buy" rating in a research report on Friday. Piper Sandler decreased their price objective on shares of DexCom from $100.00 to $90.00 and set an "overweight" rating for the company in a research report on Friday. Morgan Stanley raised their target price on DexCom from $75.00 to $82.00 and gave the company an "equal weight" rating in a research report on Friday, February 14th. Finally, Robert W. Baird reduced their price target on DexCom from $115.00 to $105.00 and set an "outperform" rating for the company in a report on Friday. Five equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $99.22.

DexCom Stock Performance

Shares of DexCom stock opened at $81.62 on Monday. The business's 50 day moving average price is $71.46 and its 200 day moving average price is $76.87. The company has a market cap of $32.00 billion, a price-to-earnings ratio of 57.08, a PEG ratio of 2.30 and a beta of 1.50. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. DexCom, Inc. has a one year low of $57.52 and a one year high of $132.26.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.01). The firm had revenue of $1.04 billion for the quarter, compared to analyst estimates of $1.02 billion. DexCom had a return on equity of 30.14% and a net margin of 14.29%. DexCom's revenue for the quarter was up 12.5% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.32 earnings per share. On average, research analysts predict that DexCom, Inc. will post 2.03 EPS for the current year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.